Swine influenza

Swine influenza Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Swine influenza from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Swine influenza On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Swine influenza All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Swine influenza
CDC on Swine influenza
Swine influenza in the news
Blogs on Swine influenza
Directions to Hospitals Treating Swine influenza
Risk calculators and risk factors for Swine influenza

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Orthomyxoviridae.

For more information about other influenza types, see human influenza or avian influenza

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Future or Investigational Therapies

Case Studies

Case#1

---

---

Treatment

Antiviral regimen

• Swine influenza

• 1. Condition1: Patients who have severe or progressive clinical illness

• Preferred regimen: Oseltamivir 150 mg PO bid
• Note (1): Treatment duration depends on clinical response
• Note (2): Where the clinical course remains severe or progressive, despite 5 or more days of antiviral treatment, monitoring of virus replication and shedding, and antiviral drug susceptibility testing is desirable
• Note (3): Antiviral treatment should be maintained without a break until virus infection is resolved or there is satisfactory clinical improvement
• Note (4): Patients who have severe or progressive clinical illness, but who are unable to take oral medication may be treated with oseltamivir administered by nasogastric or orogastric tube

• 2. Condition2: In situations where oseltamivir is not available, or not possible to use, patients who have severe or progressive clinical illness

• Preferred regimen: Zanamivir inhaled
• Note: Zanamivir IV should be considered where available and is recommended for those with serious or progressive illness. If not available, Peramivir IV may be considered

• 3. Condition3: Severely immunosuppressed patients

• Preferred regimen: Antiviral chemoprophylaxis by using Oseltamivir OR Zanamivir

See Also

• Swine flu at CDC

Influenza Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Influenza from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Swine influenza On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Swine influenza All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Swine influenza
CDC on Swine influenza
Swine influenza in the news
Blogs on Swine influenza
Directions to Hospitals Treating Influenza
Risk calculators and risk factors for Swine influenza